bendamustine hydrochloride has been researched along with Lymphoma, Mantle-Cell in 120 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (5.83) | 29.6817 |
| 2010's | 71 (59.17) | 24.3611 |
| 2020's | 42 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hui, M | 1 |
| Ishikawa, T; Makita, M; Moriyama, T; Murakami, H; Sunami, K; Yoshioka, T | 1 |
| Allmer, C; Ansell, SM; Castellino, A; Cerhan, JR; Cohen, JB; Farooq, U; Feldman, AL; Habermann, TM; Inwards, DJ; Larson, MC; Link, BK; Martin, P; Maurer, MJ; Nowakowski, GS; Paludo, J; Slager, SL; Syrbu, SI; Wang, Y; Witzig, TE | 1 |
| Albertsson-Lindblad, A; Eskelund, CW; Geisler, CH; Grønbaek, K; Jerkeman, M; Kolstad, A; Laurell, A; Lindberg, Å; Räty, R | 1 |
| Albertsson-Lindblad, A; Glimelius, I; Jerkeman, M; Palsdottir, T; Smedby, KE; Weibull, CE | 1 |
| Cohen, JB; Romancik, JT | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| Bosly, A; Dreyling, M; Freeman, CL; Gerrie, AS; Hermine, O; Hoster, E; Klapper, W; Ramsower, CA; Rimsza, LM; Savage, KJ; Scott, DW; Sehn, LH; Szymczyk, M; Unterhalt, M; Villa, D | 1 |
| Belada, D; Boccomini, C; Deshpande, S; Dreyling, M; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Henninger, T; Hermine, O; Hernández-Rivas, JÁ; Hong, X; Howes, A; Jerkeman, M; Jurczak, W; Kim, SJ; Le Gouill, S; Lewis, D; Mishima, Y; Özcan, M; Perini, GF; Pocock, C; Qin, R; Song, Y; Spurgeon, SE; Storring, JM; Trotman, J; Walewski, J; Wang, ML; Zhu, J; Zinzani, PL | 1 |
| Beitinjaneh, A; Bouabdallah, K; Fang, X; Flinn, IW; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Kersten, MJ; Khanal, R; Kloos, I; Locke, FL; McSweeney, PA; Miklos, DB; Munoz, J; Pagel, JM; Peng, W; Reagan, PM; Shen, RR; Siddiqi, R; Timmerman, JM; Topp, MS; Wang, M | 1 |
| Edina, BC; Rinaldi, I | 1 |
| Casulo, C; Choma, M; Drill, E; Drullinsky, P; Gerecitano, J; Grieve, C; Hamlin, P; Joffe, E; Joseph, A; Kumar, A; Laraque, L; Moskowitz, A; Moskowitz, C; Schick, D; Younes, A; Zelenetz, A | 1 |
| Cliff, ERS; Dickinson, M | 1 |
| Birtas Atesoglu, E; Ferhanoglu, B; Ozbalak, M | 1 |
| Eşkazan, AE | 1 |
| Dreyling, M; Le Gouill, S; Wang, ML | 1 |
| Choi, YS; Eom, HS; Jo, JC; Kim, SJ; Kim, WS; Kwak, JY; Lee, GW; Lee, JO; Oh, SY; Yi, JH | 1 |
| DiMaria, E; Drennan, IR; Gerard, L; Kotchetkov, R; Nay, D; Prica, A; Susman, D | 1 |
| Andreadis, C; Banerjee, R; Beitinjaneh, AM; Dahiya, S; Deol, A; Dorritie, KA; Frank, MJ; Ghobadi, A; Goy, A; Hill, BT; Jacobs, MT; Jain, MD; Jain, P; Lekakis, L; Lin, Y; Locke, FL; Maurer, MJ; Mcguirk, JP; Miklos, DB; Munoz, JL; Neelapu, SS; Oluwole, OO; Paludo, J; Rapoport, AP; Shah, B; Vose, JM; Wang, ML; Wang, T; Wang, Y | 1 |
| Sheng, Z; Wang, L | 1 |
| Jentsch-Ullrich, K; Schalk, E | 1 |
| Arcari, A; Botto, B; Bruna, R; Celli, M; Cencini, E; Chini, C; Di Rocco, A; Evangelista, A; Ferrante, M; Ferrero, S; Ghiggi, C; Merli, F; Moia, R; Patti, C; Pileri, SA; Puccini, B; Quaglia, FM; Re, A; Sciarra, R; Spina, M; Stelitano, C; Tani, M; Tisi, MC; Visco, C; Volpetti, S; Zambello, R; Zanni, M; Zilioli, VR | 1 |
| Bartlett, NL; Cashen, A; Edwin, N; Fehniger, TA; Ghobadi, A; Guy, DG; Kahl, BS; Patel, DA; Shah, NM; Trinkaus, K; Wan, F; Watkins, M | 1 |
| Ishiwata, K; Kageyama, K; Kaji, D; Mori, YA; Nishida, A; Shimizu, Y; Takagi, S; Taniguchi, S; Taya, Y; Uchida, N; Wake, A; Watanabe, O; Yamaguchi, K; Yamamoto, G; Yamamoto, H | 1 |
| Jing, C; Niu, T; Wang, J; Zhao, A | 1 |
| Owen, C; Perry, S; Peters, A; Puckrin, R; Stewart, D; Street, L | 1 |
| Du, KX; Li, JY; Li, Y; Liang, JH; Shen, HR; Wang, L; Wu, JZ; Xia, Y; Xu, W; Yin, H | 1 |
| Anglin, P; Eberg, M; Elia-Pacitti, J; Ewara, EM; Kukaswadia, A; Muratov, S; Sharma, A | 1 |
| Du, XL; Fu, S; Giordano, SH; Lairson, DR; Li, R; Wang, M; Zhao, B; Zhao, H | 1 |
| Barr, PM; Chen, RW; Fenske, TS; Friedberg, JW; Kahl, BS; Kamdar, M; Leblanc, ML; Leonard, JP; Li, H; Phillips, TJ; Rimsza, LM; Shea, TC; Smith, SM | 1 |
| Byun, JM; Eom, HS; Jo, JC; Kang, HJ; Kim, HJ; Kim, SJ; Lee, HS; Lee, JO; Lee, SI; Lee, Y; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yhim, HY; Yoo, KH | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Crosbie, N; Eyre, TA; Frewin, R; Lambert, J; McCulloch, R; McMillan, A; Phillips, N; Quaglia, FM; Rule, S; Tucker, DL; Visco, C | 1 |
| Aldrees, S; Jeeva-Patel, T; Margolin, E | 1 |
| Armand, P; Bartlett, NL; Brown, JR; Bsat, J; Cashen, A; Chase, M; Crombie, J; Davids, MS; Edwin, N; Fisher, D; Freedman, A; Ghobadi, A; Jacene, H; Jacobsen, E; Jacobson, C; Joyce, R; Kahl, B; Kim, A; LaCasce, A; Mehta-Shah, N; Merryman, RW; Ng, S; Odejide, O; Redd, R | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| den Brok, WD; Freeman, CL; Gerrie, AS; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Toze, CL; Villa, D | 1 |
| Parekh, PK; Powell, PR; Shah, RA | 1 |
| Co, M; Dreyling, M; Gouill, SL; Holmgren, E; Huang, H; Huang, J; Ladetto, M; Novotny, W; Romano, A; Smith, SD; Tam, CS; Wang, M | 1 |
| Ferreira, F; Marques, JAS; Melo, DP; Santos, M; Vaz, RP | 1 |
| Abi Hatem, N; Dameron, M; Gupta, N; Horowitz, M | 1 |
| Byfield, SD; Kabadi, SM; LE, L; Olufade, T | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Davis, K; Du, XL; Goyal, RK; Jain, P; Kabadi, SM; Kaye, JA; Le, H; Nagar, SP; Wang, M | 1 |
| Ghesani, N; Khodarahmi, I | 1 |
| Aotsuka, N; Igarashi, T; Irisawa, H; Itoh, K; Masuda, S; Tsujimura, H; Tsukasaki, K; Utsu, Y; Wakita, H | 1 |
| Martin, P | 1 |
| Bongers, KS; Ettleson, M; Marini, BL; Perissinotti, AJ; Phillips, T; Vitale, K | 1 |
| Doorduijn, JK; Kluin-Nelemans, JC | 1 |
| Imataki, O; Kadowaki, N; Uchida, S; Uemura, M; Yokokura, S | 1 |
| Appleton, S; Burton, C; Howell, D; Johnson, R; Patmore, R; Roman, E; Smith, A | 1 |
| Allen, J; Badillo, M; Lee, HJ; Ok, CY; Prabhu, V; Romaguera, JE; Sadimin, ET; Schalop, L; Schenkel, J; Tarapore, R; Wang, M; Zloza, A | 1 |
| Albertsson-Lindblad, A; Eskelund, CW; Geisler, CH; Grønbæk, K; Jerkeman, M; Kolstad, A; Laurell, A; Pedersen, LB; Räty, R | 1 |
| Edwin, NC; Kahl, B | 1 |
| Dolak, W; Kiesewetter, B; Lamm, W; Mayerhöfer, ME; Puhr, H; Raderer, M | 1 |
| Burke, JM; Chang, J; Chen, L; Flinn, IW; Hallman, D; Hawkins, T; Issa, S; Kahl, B; Kolibaba, K; MacDonald, D; Simpson, D; Trotman, J; van der Jagt, R; Wood, P | 1 |
| Cheah, CY; Marlton, P; Opat, S; Trotman, J | 1 |
| Chinen, Y; Fuchida, SI; Horiike, S; Iwai, T; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakao, M; Nishigaki, H; Ohshiro, M; Shimazaki, C; Shimura, K; Shimura, Y; Sugitani, M; Takimoto-Shimomura, T; Taniwaki, M; Uchiyama, H; Uoshima, N; Yoshida, M | 1 |
| Ballo, H; Balser, C; Banat, GA; Barth, J; Brugger, W; Dürk, H; Heil, G; Hinke, A; Hoelzer, D; Kaiser, U; Kofahl-Krause, D; Losem, C; Maschmeyer, G; Niederle, N; Roller, F; Rummel, MJ; Stauch, M; von Grünhagen, U; Weidmann, E; Welslau, M | 1 |
| Brugger, W; Ghielmini, M | 1 |
| Cabanillas, F; Rivera-Rodriguez, N | 1 |
| Chen, LS; Gandhi, V; Neelapu, SS; Yang, Q | 1 |
| Burke, JM; Chen, L; Clementi, R; Craig, M; Flinn, IW; Hallman, DM; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; Kwan, YL; Macdonald, D; Munteanu, M; Simpson, D; van der Jagt, R; Wood, P | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Bond, M; Burke, JM; Darwish, M; Hellriegel, E; Ludwig, E; Munteanu, MC; Phillips, L; Robertson, P | 1 |
| Izutsu, K; Maruyama, D; Nisikori, M; Ohmachi, K; Suzuki, T | 1 |
| Arranz, R; Cannata-Ortiz, J; Da Silva Rodriguez, C; Domingo-Domenech, E; Fernández-Fonseca, E; García-Noblejas, A; González-Lopez, TJ; Macia, S; Martínez Barranco, P; Martínez Chamorro, C; Navarro Matilla, B; Nicolás, C; Oña Navarrete, R; Panizo, C; Pérez, R; Ramírez Sánchez, MJ; Ruedas López, AM; Sánchez Blanco, JJ; Sánchez González, B | 1 |
| Ando, M; Emi, N; Inaguma, Y; Ito, K; Kakumae, Y; Okamoto, A; Okamoto, M; Tokuda, M; Yamada, S; Yanada, M | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Chen, PM; Chiou, TJ; Hou, HA; Hsiao, LT; Kuo, CY; Liu, CY; Tien, HF; Wang, MC; Wu, JH | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Atta, J; Buske, C; Dreyling, M; Hess, G; Keller, U; Kirschey, S; Klapper, W; Medler, C; Ruckes, C; Scholz, CW; Theobald, M; van Oordt, C; Witzens-Harig, M | 1 |
| Aisa, Y; Chen, K; Hagihara, M; Ishida, A; Masuda, Y; Matsumoto, K; Miyakawa, Y; Nakajima, H; Nakaya, A; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Tsukada, Y; Ueno, H; Watanabe, K; Yamada, Y; Yano, T; Yokoyama, K | 1 |
| Herishanu, Y; Katz, BZ | 1 |
| Dong, F; Ke, X; Li, H; Wan, W; Wang, J; Wang, Y; Wu, F; Yan, X; Zhang, W; Zhu, M | 1 |
| Burke, JM; Chen, L; Craig, MD; Flinn, IW; MacDonald, DA; Morganroth, J; Munteanu, MC; van der Jagt, RH | 1 |
| Becker, M; Bruch, HR; Frank, M; Reeb, M; Schwinger, U; Straßl, L; Tschechne, B | 1 |
| Czuczman, MS; Goy, A; Graf, DA; Lamonica, D; Munteanu, MC; van der Jagt, RH | 1 |
| Fukuhara, S; Kitahara, H; Kobayashi, Y; Maeshima, AM; Makita, S; Maruyama, D; Miyamoto, K; Munakata, W; Saito, H; Suzuki, T; Taniguchi, H; Tobinai, K | 1 |
| Hagiwara, K; Iida, H; Nagai, H; Tokunaga, T | 1 |
| Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M | 1 |
| Cieplik, HC; Dreyling, M; Hess, G; Hutter, G; Weiglein, T; Zimmermann, Y; Zoellner, AK | 1 |
| Armand, P; Brown, JR; Bsat, J; Davids, MS; Faham, M; Fisher, DC; Freedman, AS; Giardino, A; Jacobsen, ED; Jacobson, C; Joyce, R; LaCasce, AS; Mayuram, S; Redd, R; Weng, L; Wilkins, J | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Burke, JM; Craig, M; Flinn, IW; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; MacDonald, D; Munteanu, M; Simpson, D; van der Jagt, RH; Victor, TW; Wood, P | 1 |
| Centeno-Haro, M; Marí-Jimenez, P; Martínez-Losada, C; Perez-Seoane, C; Rodríguez-García, G; Sánchez-García, J | 1 |
| Czuczman, MS; Graf, DA; Lamonica, D; Munteanu, MC | 1 |
| Munakata, W; Tobinai, K | 1 |
| Lipsky, A; Martin, P | 1 |
| Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J | 1 |
| Arcari, A; Botto, B; Carmichael, J; Ceccarelli, M; Cellini, C; Drandi, D; Fanin, R; Ferranti, A; Ferrari, A; Ferrero, S; Ladetto, M; Liberati, AM; Minotto, C; Montechiarello, E; Musuraca, G; Patti, C; Pileri, SA; Salvi, F; Spina, M; Stelitano, C; Volpetti, S; Zaja, F | 1 |
| Cheson, BD; Cohen, P; Herst, JA; Lemieux, B; Robinson, KS; Schwartzberg, LS; Tulpule, A; van der Jagt, RH; Williams, ME | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Milpied, P; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N | 1 |
| Kahl, BS | 1 |
| Czuczman, MS; Leonard, JP; Williams, ME | 2 |
| Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H | 1 |
| Ando, K; Choi, I; Ishizawa, K; Itoh, K; Kubota, N; Nagai, H; Ogura, M; Ohmachi, K; Terui, Y; Tobinai, K; Uchida, T; Uike, N; Uoshima, N; Usuki, K; Watanabe, T; Yamamoto, J | 1 |
| Garnock-Jones, KP | 1 |
| Ishizawa, K; Ogura, M; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K | 1 |
| Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F | 1 |
| Benn, P; Bilgrami, SF; Delach, JA; Kahl, BS; Kourelis, TV | 1 |
| Gregory, SA; Rummel, MJ | 1 |
| Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Wada, T | 1 |
| Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C | 1 |
| Alizadeh, AA; Hosein, PJ; Lossos, IS; Maeda, LS; Warsch, S | 1 |
| Chang, JE; Kahl, BS | 1 |
| Asaka, M; Imamura, M; Miyashita, N; Ogasawara, R; Tanaka, J; Tsutsumi, Y | 1 |
| Akazawa, Y; Imaizumi, Y; Isomoto, H; Matsushima, K; Miyazaki, Y; Nakao, K; Niino, D; Norimura, D; Ohnita, K; Shikuwa, S; Takeshima, F; Tsukasaki, K; Yamaguchi, N | 1 |
| Benveniste, R; Chapman, JR; Hosein, PJ; Lossos, IS; Morris, MI; Teomete, U; Warsch, S | 1 |
| Deng, C; Lee, S; O'Connor, OA | 1 |
| Ogura, M | 1 |
| Korycka-Wołowiec, A; Robak, T | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| D'Amore, ES; Finotto, S; Menin, A; Paolini, R; Pizzolo, G; Rodeghiero, F; Semenzato, G; Visco, C; Zaja, F; Zambello, R; Zanotti, R | 1 |
| Hoelzer, D; Mitrou, PS; Rummel, MJ | 1 |
| Al-Batran, SE; Chow, KU; Dürk, H; Hansmann, ML; Hecker, R; Hoelzer, D; Josten, KM; Kim, SZ; Kofahl-Krause, D; Mitrou, PS; Neise, M; Rost, A; Rummel, MJ; von Grünhagen, U; Welslau, M | 1 |
| Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C | 1 |
| Aldaoud, A; Dreyling, M; Haak, U; Hess, G; Heymanns, J; Hiddemann, W; Huber, C; Köppler, H; Losem, C; Schmitz, S; Thomalla, J; Unterhalt, M; Weide, R | 1 |
20 review(s) available for bendamustine hydrochloride and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Sequencing of Novel Therapies for Mantle Cell Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Glucocorticoids; Humans; Immunotherapy, Adoptive; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Proteasome Inhibitors; Protein Kinase Inhibitors; Receptors, Chimeric Antigen; Rituximab; Stem Cell Transplantation; Sulfonamides; Transplantation, Autologous; Transplantation, Homologous | 2021 |
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2022 |
Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Network Meta-Analysis; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2023 |
Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rituximab | 2023 |
Optimizing therapy for mantle cell lymphoma.
Topics: Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab | 2017 |
What is the optimal initial management of the older MCL patient?
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Prednisone; Rituximab; Survival Rate; Vincristine | 2018 |
Evolving treatment strategies in mantle cell lymphoma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Neoplasm, Residual; Rituximab; Stem Cell Transplantation | 2018 |
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Topics: Australia; Bendamustine Hydrochloride; Disease Management; Helicobacter Infections; Helicobacter pylori; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Randomized Controlled Trials as Topic; Rituximab | 2019 |
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Germany; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Practice Guidelines as Topic; Rituximab | 2013 |
Recent advances in the management of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Patient Selection; Phosphatidylinositol 3-Kinases; Prognosis; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
[Recommendation for the optimal use of bendamustine in Japan].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cytomegalovirus Infections; Drug Administration Schedule; Drug Eruptions; Evidence-Based Medicine; Hepatitis B; Humans; Immunocompromised Host; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Nausea; Nitrogen Mustard Compounds; Opportunistic Infections; Rituximab; Vasculitis | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Design; Drug Discovery; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome | 2009 |
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Bendamustine's emerging role in the management of lymphoid malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2011 |
[Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2011 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisolone; Prognosis; Remission Induction; Rituximab; Survival Rate; Vincristine | 2002 |
32 trial(s) available for bendamustine hydrochloride and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Quality of Life; Rituximab; Survival Rate | 2022 |
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ki-67 Antigen; Lactate Dehydrogenases; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2022 |
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Survival Analysis | 2022 |
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell | 2022 |
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Safety; Survival Rate; Treatment Outcome | 2021 |
Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biomarkers; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2018 |
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Rituximab; Survival Rate; Tumor Suppressor Protein p53 | 2018 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Vincristine | 2019 |
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytomegalovirus Infections; Dexamethasone; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Rituximab; Salvage Therapy; Young Adult | 2019 |
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2013 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Nitrogen Mustard Compounds; Paresthesia; Peripheral Nervous System Diseases; Prednisone; Rituximab; Treatment Outcome; Vincristine; Vomiting | 2014 |
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Taiwan | 2015 |
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Rituximab; Safety; Sirolimus; Survival Rate | 2015 |
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2015 |
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Electrocardiography; Female; Heart Rate; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2015 |
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Germany; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Prospective Studies; Time Factors | 2015 |
Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Rate; Time Factors | 2015 |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2016 |
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate | 2016 |
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Surveys and Questionnaires; Vincristine | 2016 |
18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2017 |
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2017 |
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Retreatment; Rituximab; Thalidomide; Treatment Outcome | 2017 |
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Gastrointestinal Diseases; Headache; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2008 |
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lung Diseases, Interstitial; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Neutropenia; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2010 |
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Pneumonia; Recurrence; Treatment Outcome; Vomiting | 2010 |
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve | 2011 |
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab | 2011 |
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting | 2013 |
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Risk Assessment; Rituximab; Single-Blind Method; Survival Rate; Treatment Outcome | 2005 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
68 other study(ies) available for bendamustine hydrochloride and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Nitrogen Mustard Compounds; Rituximab | 2022 |
Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Rituximab; Salvage Therapy | 2021 |
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Prospective Studies; Rituximab; Vincristine | 2022 |
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Rituximab; Sweden; Vincristine | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Topics: Adult; Bendamustine Hydrochloride; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen | 2023 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma. Reply.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Topics: Adult; Aged; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Republic of Korea; Retrospective Studies; Rituximab | 2022 |
Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab | 2023 |
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Topics: Adult; Antigens, CD19; Bendamustine Hydrochloride; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen | 2023 |
Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Frail Elderly; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Rituximab | 2023 |
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cytarabine; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Prospective Studies; Rituximab | 2023 |
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pilot Projects; Rituximab | 2023 |
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine | 2023 |
Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Feasibility Studies; Humans; Lymphoma, Mantle-Cell; Receptors, Chimeric Antigen | 2023 |
[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada.
Topics: Adult; Bendamustine Hydrochloride; Cost of Illness; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Ontario; Patient Acceptance of Health Care; Retrospective Studies; Rituximab | 2023 |
Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Neoplasm Staging; Rituximab; SEER Program; Treatment Outcome | 2019 |
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Child, Preschool; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Prognosis; Rituximab; Treatment Outcome; Vincristine | 2019 |
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prednisone; Radiotherapy; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Time Factors; Vincristine | 2020 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Rituximab | 2020 |
Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Fundus Oculi; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Optic Nerve; Optic Nerve Diseases; Rituximab | 2020 |
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Retrospective Studies; Rituximab; Transplantation, Autologous | 2020 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Rituximab; Transplantation, Autologous | 2020 |
What lies beneath: Cutaneous involvement of mantle cell lymphoma underlying an insect-bite-like reaction.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Awareness; Bendamustine Hydrochloride; Biopsy; Bone Marrow; Cyclin D1; Diagnosis, Differential; Humans; Immunophenotyping; Insect Bites and Stings; Lymphoma, Mantle-Cell; Male; Rituximab; Skin Diseases; Translocation, Genetic; Treatment Outcome | 2021 |
Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Male; Palatine Tonsil; Rituximab; Tonsillar Neoplasms | 2021 |
When to consider Pneumocystis jirovecii prophylaxis in HIV-negative patients.
Topics: Aged; Anti-Bacterial Agents; Bendamustine Hydrochloride; HIV Seronegativity; Humans; Immunocompromised Host; Lung Diseases, Interstitial; Lymphoma, Mantle-Cell; Male; Opportunistic Infections; Pneumonia, Pneumocystis; Prednisone; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Rituximab; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Doxorubicin; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Prednisone; Renal Insufficiency; Retrospective Studies; Rituximab; Stroke; Vincristine | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Delivery of Health Care; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Medicare; Prednisone; Retrospective Studies; Rituximab; United States; Vincristine | 2021 |
Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
Topics: Bendamustine Hydrochloride; Female; Humans; Immunophenotyping; Lacrimal Apparatus; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Remission Induction; Rituximab; Subcutaneous Tissue | 2017 |
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Male; Renal Dialysis | 2019 |
Bendamustine and G-CSF support.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy-Induced Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Mantle-Cell; Male; Rituximab | 2019 |
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; United Kingdom | 2018 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dopamine D2 Receptor Antagonists; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Male; Molecular Targeted Therapy; Neoplasm Proteins; Oligopeptides; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Rituximab; Stress, Physiological; Vincristine | 2019 |
Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Evaluation; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Remission Induction; Retreatment; Retrospective Studies; Risk; Rituximab | 2019 |
Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Humans; Imidazoles; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-pim-1; Pyridazines | 2013 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2014 |
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Salvage Therapy; Spain; Treatment Failure | 2014 |
Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Female; Humans; Immune System; Lymphocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome | 2015 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Blood Platelets; Chemical Precipitation; Cryoglobulins; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Piperidines; Platelet Count; Pyrazoles; Pyrimidines; Rituximab; Thrombocytopenia | 2015 |
B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7 Antigens; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Female; Gene Silencing; Humans; Lymphoma, Mantle-Cell; Mice; Neoplasms, Experimental; Rituximab | 2015 |
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2015 |
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Topics: Adenine; Bendamustine Hydrochloride; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Drug Synergism; G1 Phase; Humans; Lymphoma, Mantle-Cell; Male; Rituximab; Sirolimus | 2016 |
A rare composite lymphoma: follicular and in situ mantle cell.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Composite Lymphoma; Female; Humans; Lymph Nodes; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Remission Induction; Rituximab; Treatment Outcome | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Bendamustine-rituximab in mantle cell lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab | 2017 |
Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Caspases; Female; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Nitrogen Mustard Compounds; Oxidative Stress; Signal Transduction; Tumor Cells, Cultured | 2008 |
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Protein Kinase Inhibitors; Rituximab; TOR Serine-Threonine Kinases; Vincristine | 2010 |
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Topics: Bendamustine Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Thalidomide; TOR Serine-Threonine Kinases | 2010 |
Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Rituximab | 2011 |
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Synergism; Flow Cytometry; Humans; Lymphoma, Mantle-Cell; Mitochondria; Nitrogen Mustard Compounds | 2012 |
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2012 |
Bendamustine: more ammunition in the battle against mantle cell lymphoma.
Topics: Bendamustine Hydrochloride; Female; Humans; Lymphoma, Mantle-Cell; Male; Nitrogen Mustard Compounds | 2012 |
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2012 |
Duodenal involvement of mantle cell lymphoma observed by magnified endoscopy with narrow-band imaging.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Color; Duodenal Neoplasms; Duodenoscopy; Humans; Image Enhancement; Lymphoma, Mantle-Cell; Male; Nitrogen Mustard Compounds | 2012 |
Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biopsy; Brain; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Nitrogen Mustard Compounds; Rituximab | 2012 |
New strategies in the treatment of mantle cell lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Stem Cell Transplantation; Syk Kinase; Tumor Microenvironment | 2012 |
[II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2012 |
Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
Topics: Administration, Intravenous; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Drug Evaluation; Europe; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; United States | 2012 |